Background: Hereditary angioedema (HAE) triggered by estrogen related to women and their life milestones. Objective: This study aimed to establish a relationship between hereditary angioedema and estrogen in women at puberty, pregnancy or on contraceptives use, their mean age at onset of manifestations, age at diagnosis, and signs and symptoms associated with the precipitating factors for HAE. Data source: Systematic review of articles in English and Portuguese using the Virtual Health Library, Google Scholar, PubMed, and Springer from 2009 to 2019. The descriptors were "hereditary angioedema," "female," and "contraceptive", combined by the boolean operator "AND". Methods: Case reports and clinical studies on HAE in women were selected. The articles were selected by reading the title and abstract, followed by followed by integral reading, where theses, dissertations, book chapters, grey literature, and review articles were excluded. Information on age, number of people, symptomatology, life stages, and precipitating factors for HAE crises were collated in a table. Results: The mean age of the women was 28.63 years; no postmenopausal case related to hormone replacement therapy was observed. Pregnancy was majorly affected, followed by the phase with use of oral contraceptives, puberty, and eventually menstrual periods. The most evident signs and symptoms were facial edema, 344 abdominal pain, and subcutaneous manifestations, with cases of airway involvement, specifically during pregnancy. Conclusion: The HAE symptoms initially appear, mostly during puberty, and worsen during the menstrual periods. The worst edemigenic attacks were noticed during pregnancy, confirming that estrogen is an important precipitating and aggravating factor triggering HAE.
Introduction
In nineteenth century, a physician named Heinrich Quincke was the first to report the clinical occurrence of hereditary angioedema (HAE) [1] [2] [3] . After six years, the Canadian physician and researcher, Willian Osler, revealed the genetic association of the disease as autosomal dominant [4] [5] [6] [7] [8] . In the term angioedema, "angio" originates from the Greek word aggeion, which expresses the idea of a blood vessel or lymphatic vessel, whereas "edema" originates from the Greek word oidema that indicates swelling [9] . This disease occurs due to the deficiency in the C1 esterase inhibitor gene (C1-INH), which binds directly to the four pillars of body function (i.e., complement, coagulation, kinin, and fibrinolysis). The symptoms vary based on whether bradykinin is in excess, ranging from mild mucosal edema to abdominal discomfort and eventually to edema crisis, with multiple organs involved varying with the edema intensity [10, 11] , and in certain cases, leading to the obstruction of upper airways [11] .
There is no cure reported for angioedema; however, in the last guideline for the diagnosis and treatment of HAE 2017 [12] , prophylaxis was emphasized to comprise mild manifestations of the disease with the use of androgens and antifibrinolytics. During emergencies, the use of plasma-derived C1-INH concentrate (cpdC1-INH), Ecallantide, and Icatibanto is used; however, only Ecallantide is not commercialized in the Federative Republic of Brazil and in the absence of the aforementioned three compounds, fresh frozen plasma (FCC) [12] is used.
Notably, in any kind of pathology, developmental triggers commonly related to the onset of edemigenic sensations, such as emotions, sex hormones (estrogen, progesterone, and testosterone), climatic changes, trauma and infections, can be identified. Regarding prevalence, there are discrepant data that fluctuate in the sphere of 1 per 50,000 inhabitants to 1 per 150,000 [14] .
The association of estrogen with certain traits of this condition remains unclear. Nevertheless, such assessment is indispensable in diagnostic evaluation and has a high theoretical value, since it is based on case reports and reviews indicating that women are more affected by this disorder than men.
When a new case is diagnosed, the patient is encouraged to perform genetic tests to rule out the histaminergic reactions or to relate the illness-person-stimulus to close the case. In particular, women are the reference who at different stages of life (puberty, combined oral contraceptive (COC) use, contraceptive phase, pregnancy, and menopausal hormone replacement), at which times they were identified with HAE. It is evident that all the aforementioned phases have estrogen in common.
Data on the pathophysiology of estrogen activating HAE is unclear; however, information will be revealed to the general public and also to patients who have not yet been diagnosed with HAE, but rather to anaphylaxis, and that on several occasions the hormonal factor triggered the attacks. Therefore, the review provides additional data to the health professionals and the general public about the reduced estrogen-angioedema ratio in clinical settings where the primary suspect was an allergy.
Hence, the main objective is to mention the life stages in which the estrogen influenced larger edemigenic attacks in women. Moreover, to describe which are they the symptoms according to age, number of people involved in the research (n) of several studies; consequently, cooperating with patients on information regarding HAE.
Material and Methods
We searched PubMed, Springer, Google Scholar, and Virtual Health Library (VHL) databases. The descriptors used were "hereditary angioedema", "female", "oral contraceptive" or "contraceptive" and "C1 inhibitor", combined by the Boolean operator AND. We selected articles with HAE clinical studies or case reports in women at puberty, during contraceptive use, gestation, or hormone replacement. The studies were selected The articles were selected by reading the title and abstract, followed by a thorough reading of the entire article. The following information was extracted from the selected articles: number of people, age, symptoms, life stages, and precipitating factor of HAE.
In total, 192 articles were selected, of which 21 redundant articles were removed. Next, 139 articles were excluded after reading the title and abstract. After a thorough reading, 19 articles were removed as they were systematic reviews. About 13 reports were found with predominant information about women and the use of estrogen (Flow Chart I).
Results
About 76.92% of the studies reported only on women using exogenous estrogen or endogenous precipitation such as pregnancy and menstruation. The remaining 23.08% have evaluation of both men and women, there is no focus in the specific life stage, but they emphasize in detail precipitating factors. In general, 38.41% were clinical studies and 61.53% were case reports.
On analyzing all the studies, 463 patients were investigated, aged between 9 and 76 years, with a mean age of 28.63 years. As presented in Table 1 , we noticed no postmenopausal cases, despite the studies reporting women older than 50 years, and the correlation between HAE and hormone replacement was not defined. The major phase when HAE occurred in women was pregnancy (seven reports), followed by six cases with COC use, and five reports of puberty and periods of menstruation. Only one case revealed a combination of COC use and worsening of HAE during menstruation.
The clinical signs and symptoms are presented in Table   1 ; these included facial edema affecting the lips, neck, and causing some dyspnea in 100% of cases, followed by abdominal cramps and subcutaneous manifestations of angioedema.
The life stage did not determine any specific sign or symptom in the patients; however, notably, the edemigenic attacks in pregnancy are linked directly to the airways. The main precipitating factor is related to the exogenous use of estrogen; however, any factor that alters the body homeostasis and also elevates the estrogen receptors, acts as a trigger for HAE crises. The study by Zotter et al. [11] Three patients in the study presented with a greater number of edemigenic crises, since they were pregnant.
COC: oral contraceptive; X: without reports in the article
Twenty-one percent of women during pregnancy or with use of estrogen contraceptives had edema only during these phases, whereas 67% had attacks even outside these referred conditions.
Ferreira et al. [26] reported about a 26-year-old female patient with severe colic type abdominal pain, sudden, recurrent, and diffuse onset associated with nausea, softened stools, edema of hands, feet, and eyelids. The 
Discussion
Among the clinical studies analyzed, most referred to the involvement of edematous crises in women. In accordance with our results, Caballero et al. [27] reported that, although the symptoms vary widely between the individuals (men and women), women are affected with greater severity.
There is evidence that female sex hormones are part of the cascade regulation that promotes HAE. The mechanism of action is due to estrogen affecting the kallikrein-kinin system and the coagulation system, increasing factor XII levels and function; the levels of pre-kallikrein, kallikrein, and high molecular weight kininogen are also elevated; all of these factors are linked to bradykinin formation. Estrogens positively regulate the expression and enhance B2 bradykinin receptor activity [28] .
Saule et al. [19] reported 55 patients, of which 14 had symptoms started at puberty, and Iahn-Aun et al. [22] reported the case of two patients who also presented symptoms in this same phase. In some of these women, the attacks became more frequent with menstruation.
Similarly, the study by Bouillet et al. [10] confirmed that the symptoms of higher severity occur during puberty and certain edemigenic attacks are reported after or during menstruation [29] .
The hormonal regulation of the disorder for HAE was supervised in the European PREHEEAT [29] (new methods for prevention and treatment of attacks in patients with HAE), where 150 patients with secondary HAE to C1 inhibitory serine protease deficiency (C1-INH), were studied [29] . The estrogenic influence of puberty, menstruation, and menopause was examined.
In 62% of cases, puberty was harmful to the patient, The clinical course and HAE symptoms follow a pattern that closely resembles patients. Most cases are diagnosed in childhood or adolescence, and worsening of edema occurs with puberty and persists throughout the patient's life [32] . In all studies, edema was described as a symptom, affecting only the facial area and/or any part of the body; in eight of these cases, a VAS involvement was observed requiring intervention.
In 9 of the 13 patients, abdominal pain was reported.
According to Bork et al. [32] , subcutaneous edema are the most common and can affect extremities in most patients, accompanied by the face and genitals, and more rarely trunk and neck [32, 33] ; however, abdominal pain in this same analysis is recurrent, and edema of the gastrointestinal tract was reported in 70%-90% of patients with AHF, [33] when they became intermittent, with severe cramps followed by vomiting and diarrhea, which was reported by Ferreira et al. [26] .
Eventually, the laryngeal symptoms, according to Bork et al. [32] are rare and potentially fatal. Less than 1% of all edema will involve the larynx, with approximately half of all patients with HAE having an edematous attack at some point in their lives. In accordance to the aforementioned results, notably, even though the laryngeal symptoms are rare, the present study demonstrated that 100% of the patients were affected in several degrees, some with greater and others with lesser severity.
Conclusions
The present study demonstrated that mostly the Finally, it is verified when taking into account the sum of all the studied patients, in some clinical studies estrogen is an important precipitating and aggravating factor that triggers HAE attacks.
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